Successful Treatment of Liver Aspergilloma by Caspofungin Acetate First-Line Therapy in a Non-Immunocompromised Patient

Abstract

Aspergillosis remains to be a life-threatening complication in immunocompromised patients. However, <em>Aspergillus</em> infection can be observed in non-immunocompromised individuals in rare cases. We report a case of liver aspergilloma in a chronic aplastic anemia patient under relatively intact immune status. Therapeutic strategy for this rare condition was extensively discussed and caspofungin acetate single agent first-line therapy was applied after careful consideration. Encouraging clinical and radiologic improvements were achieved in response to the antifungal salvage. Our long-term follow-up study also revealed a favorable prognosis. Based on this experience, we suggest caspofungin acetate as first-line therapy for treatment plans of liver aspergilloma.

Keywords

• aspergillosis
• liver
• &lt;em&gt;Aspergillus&lt;/em&gt;&lt;em&gt; fumigatus&lt;/em&gt;
• caspofungin acetate